Welcome to our dedicated page for Alcon SEC filings (Ticker: ALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alcon Inc.'s SEC filings document its status as a foreign private issuer and the formal disclosures supporting its eye care operations. Form 6-K reports include interim financial reports, annual report materials, press-release exhibits and AGM invitations covering the Surgical and Vision Care franchises, product-launch activity, segment sales, earnings measures, cash flow, R&D, tariffs, acquisitions and integration items.
The filings also record governance and capital-structure matters, including annual shareholder votes, board and compensation committee elections, compensation approvals, dividends, share repurchase authorizations, issued capital, reserves and borrowing-facility data reported in XBRL.
Alcon Inc. reported first-quarter 2026 net sales of $2.7 billion, up 10% year over year and 6% in constant currency. Surgical sales rose 10% to $1.5 billion and Vision Care grew 9% to $1.2 billion, driven by new products like Unity, PanOptix Pro, Tryptyr and Precision7.
Reported diluted EPS fell to $0.39 from $0.70, mainly because the prior year included $142 million of investment remeasurement gains, while core diluted EPS increased 16% to $0.85 as core operating margin improved to 21.2%. Operating income declined to $292 million as efficiency initiative costs, a $38 million intangible impairment and higher tariffs offset strong core performance.
Alcon generated $418 million of operating cash flow and $279 million of free cash flow. Shareholders approved a dividend of 0.28 CHF per share, and the board authorized up to $1.5 billion of share repurchases over three years, subject to Swiss Takeover Board authorization. The company maintained 2026 guidance for 5–7% constant-currency sales growth and core operating margin expansion, and slightly raised its constant-currency core EPS growth outlook to 10–13%.
Alcon Inc. has set the agenda for its April 30, 2026 Annual General Meeting, where shareholders will vote on 2025 financial statements, board discharge and governance items. The Board is proposing a gross cash dividend of CHF 0.28 per share, with a maximum total of CHF 139.916 million based on 499,700,000 issued shares. Ex‑dividend trading is expected to start on May 5, 2026 for shares held through SIX SIS and May 6, 2026 for shares held through DTC, with Swiss payout around May 7, 2026 and 35% withholding tax.
Shareholders will also vote on a non‑binding approval of the 2025 Report on Non‑Financial Matters, consultative approval of the 2025 Compensation Report, and binding caps of CHF 4.275 million for Board compensation (2026–2027 term) and CHF 47.1 million for Executive Committee compensation for 2027. The agenda includes re‑election of all current directors and election of former Cisco CFO R. Scott Herren as a new independent Board member, re‑election of Compensation Committee members, the independent representative Hartmann Dreyer, and PricewaterhouseCoopers SA as statutory auditors for 2026.
Form 144 notice filed relating to common stock through Fidelity Brokerage Services LLC. The filing lists planned transactions tied to restricted stock vesting dated 02/18/2023, 03/13/2023, and 02/17/2024 with quantities 183, 1,204, and 1,025 shares respectively. Broker contact is shown as Fidelity Brokerage Services LLC.
Alcon Inc. reports that 2025 was a transformative year, combining steady financial growth with a surge in innovation and social impact. Net sales reached $10.3 billion, up 5% as reported, or 4% on a constant currency basis. Diluted EPS was $1.98, with core diluted EPS of $3.07.
The company generated $2.3 billion in cash from operating activities and $1.7 billion in free cash flow, returning $848 million to shareholders via buybacks and dividends. Management highlights more than 10 significant product launches, including the Unity VCS surgical platform, PanOptix Pro intraocular lens, and TRYPTYR dry eye therapy, alongside strategic acquisitions such as LumiThera and Aurion Biotech.
Alcon emphasizes governance, board refreshment with the addition of Deborah Di Sanzo, and expanded social impact. In 2025 it completed 150,000 vision screenings for schoolchildren and improved or restored vision for over 5 million people with untreated cataracts, while setting new 2030 goals to broaden access and professional training.
Alcon Inc. filed its annual Form 20-F, providing a detailed overview of its global eye care business and risk profile for the year ended December 31, 2025. The company reports 487,427,920 ordinary shares outstanding as of the period end.
Alcon prepares consolidated financial statements in US dollars under IFRS as issued by the IASB and is listed on the NYSE and SIX Swiss Exchange. The report explains its focus on surgical ophthalmic devices, contact lenses and ocular health products, excluding spectacles and most prescription drugs.
The filing devotes extensive space to risk factors, highlighting cybersecurity and cloud-migration vulnerabilities, ethical and regulatory challenges from artificial intelligence, complex data privacy rules, and reliance on global supply chains and single-source suppliers. It also describes competitive pressures, heavy R&D needs, acquisition integration risks, exposure to China and other volatile markets, evolving healthcare reimbursement regimes, environmental and product-quality regulation, substantial goodwill and debt levels, and increasing complexity in global tax and sustainability requirements.
Alcon Inc. reported solid 2025 growth but softer margins and EPS as it invested behind new products and faced higher tariffs. Net sales reached $10.3 billion, up 5% year over year, with fourth‑quarter sales of $2.7 billion, up 9% on a reported basis and 7% in constant currency.
Full‑year operating income was $1.4 billion, down 4%, and diluted EPS slipped to $1.98 from $2.05, while core diluted EPS edged up to $3.07 from $3.05. The company generated $2.3 billion of operating cash flow and $1.7 billion of free cash flow, returning $848 million to shareholders via dividends and share repurchases, and completing a $750 million buyback program.
Alcon highlighted growth in Surgical consumables and equipment and in Vision Care, especially dry‑eye products and contact lenses, even as tariffs and higher R&D and marketing spend weighed on margins. For 2026, it targets constant‑currency net sales growth of 5%–7% and core diluted EPS growth of 9%–12%, supported by about $100 million of efficiency savings and continued new product launches.
Alcon and STAAR Surgical have agreed to an amended all-cash merger under which Alcon will acquire all outstanding STAAR shares for $30.75 per share, valuing the equity at about $1.6 billion.
The revised price adds roughly $150 million of equity value and represents a 74% premium to STAAR’s 90-day volume-weighted average price and a 66% premium to the August 4, 2025 closing price. Both boards have approved the deal, and STAAR’s board recommends that stockholders approve the transaction.
A prior “go-shop” process ended without a superior offer. Alcon plans to fund the purchase with short- and long-term credit facilities and expects the transaction to be accretive to earnings in year two, with closing anticipated in early 2026, subject to regulatory and STAAR stockholder approvals and other customary conditions.
Alcon and STAAR Surgical have agreed to an amended all-cash merger under which Alcon will acquire all outstanding STAAR shares for $30.75 per share, valuing the equity at about $1.6 billion.
The revised price adds roughly $150 million of equity value and represents a 74% premium to STAAR’s 90-day volume-weighted average price and a 66% premium to the August 4, 2025 closing price. Both boards have approved the deal, and STAAR’s board recommends that stockholders approve the transaction.
A prior “go-shop” process ended without a superior offer. Alcon plans to fund the purchase with short- and long-term credit facilities and expects the transaction to be accretive to earnings in year two, with closing anticipated in early 2026, subject to regulatory and STAAR stockholder approvals and other customary conditions.